One year after the groundbreaking asthma guidelines were introduced, a shocking reality persists: countless individuals still face delayed diagnoses due to a widespread lack of access to essential testing. But here's where it gets controversial—while the guidelines have undeniably improved asthma care, a new report from Asthma and Lung UK reveals that systemic barriers continue to hinder progress. And this is the part most people miss: despite promising advancements, structural and resource challenges are still leaving patients in the lurch.
The report, released in December 2025, dives deep into the state of asthma care one year after the implementation of the chronic asthma guideline. Based on clinician interviews and thorough analysis, it highlights both the successes and the persistent gaps. For instance, the guideline’s recommendation to prescribe a low-dose combination of inhaled corticosteroids (ICS) with formoterol for newly diagnosed patients over 12 has shown early promise. This approach not only reduces inflammation but also alleviates symptoms more effectively than traditional methods. But here’s the catch: the report boldly asserts that short-acting beta-2 agonists (SABA) inhalers should never be prescribed without ICS—a point that’s sure to spark debate among healthcare providers.
The shift to anti-inflammatory reliever (AIR) and maintenance and reliever therapy (MART) has been a game-changer, with patients reporting better satisfaction, adherence, and overall asthma control. Yet, the report underscores a critical issue: many patients feel unsupported during the transition, leading to poor adherence and knock-on problems. Is this a failure of the system, or a natural growing pain in adopting new treatments?
Another glaring issue is the lack of access to diagnostic tools like FeNO and spirometry testing. Clinicians report increased confidence in diagnosing asthma, but without these tests, delays in diagnosis and poorer outcomes are inevitable. This disparity raises a troubling question: Are we inadvertently creating a two-tiered system where only some patients receive timely, effective care?
Asthma and Lung UK has responded with actionable recommendations, including widespread access to point-of-care FeNO testing and personalized asthma action plans. Darush Attar-Zadeh, a clinical fellow respiratory pharmacist, notes that these challenges are all too real, particularly in regions like north west London, where diagnostic testing remains a significant hurdle. He emphasizes the importance of shared decision-making when switching patients to new regimens, cautioning against dangerous ‘blanket switching.’
Meanwhile, the approval of depemokimab, a twice-yearly biological medicine for severe asthma, marks a leap forward in treatment options. Administered via subcutaneous injection, it targets type 2 inflammation, offering hope for patients with limited alternatives. But will this innovation reach those who need it most, or will it exacerbate existing inequities?
As we celebrate the progress made, it’s clear that the fight for equitable, effective asthma care is far from over. What’s your take? Do the benefits of these advancements outweigh the challenges, or is the system still failing too many? Let’s spark a conversation in the comments—your perspective could be the missing piece in this complex puzzle.
